According to the epidemiologic investigation by Peking University Institute of Nephrology, the prevalence rate of CKD by 2012 in China was 10.8%.[13] Yet by 2016, the total population of CKD published by National Bureau of Statistic in China reached nearly 147 million.[14] However, the therapeutic options for CKD are very limited, such as protein, salt and lipid intake restriction, blood pressure control and angiotensin II receptor blockers or angiotensin converting enzyme inhibitors administration, and the efficacy is not satisfactory though. The gene discussed is ACE; the disease is chronic kidney disease.